semaglutide and dialysis semaglutide can result in weight loss in hemodialysis patients - Semaglutidein renal failure Semaglutide Semaglutide and Dialysis: Navigating Efficacy, Safety, and Potential Benefits

The use ofsemaglutidein patients with renal failure a retrospective cohort study The intersection of semaglutide use and patients undergoing dialysis presents a complex yet promising area of medical research. As a glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide has demonstrated significant efficacy in managing type 2 diabetes and promoting weight loss.2024年10月7日—Semaglutidetreatment resultedin significant reduction in weight and BMI in patients with obesityundergoingdialysis, while maintaining an acceptable side ... Emerging evidence suggests its potential benefits extend to individuals with chronic kidney disease (CKD) and those requiring hemodialysis or peritoneal dialysis.Weight loss drug proves effective in hemodialysis patients with ... This article delves into the current understanding of semaglutide and dialysis, exploring its safety profile, effectiveness in weight management, glycemic control, and potential impact on kidney outcomes.

Understanding Semaglutide's Role in Kidney Health

Semaglutide, a medication primarily known for its role in diabetes management and weight reduction, is increasingly being studied in populations with compromised kidney function.Keeping kidneys FLOWing – semaglutide improves renal ... Research indicates that semaglutide can offer several advantages for patients with CKD, including improved glycemic control and a reduction in cardiovascular events作者：L Vanek·2024·被引用次数：24—Semaglutidetreatment resulted in significant reduction in weight and BMI in patients with obesity undergoingdialysis, while maintaining an acceptable side .... A notable study, the FLOW trial, demonstrated that semaglutide 1 mg significantly reduced the risk of major CKD outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease, highlighting its potential to preserve renal function.作者：J Couture·2025·被引用次数：5—This study suggests thatsemaglutide promotes weight loss in hemodialyzed adultswith obesity, but discontinuation of treatment was frequent and common adverse ...

For individuals on dialysis, the burden of obesity is often exacerbated, leading to various health complications作者：MW Taal·2025·被引用次数：13—Nevertheless, treatment withsemaglutideshould already be considered in persons with type 2 diabetes and CKD who are intolerant of SGLT2i and/ .... Studies are now exploring how semaglutide can address this challenge. For instance, research by Vanek et al. has shown that semaglutide treatment resulted in significant reduction in weight and BMI in patients with obesity undergoing dialysis, while maintaining an acceptable side effect profile. This is crucial, as effective weight management can improve overall health and potentially enhance transplant candidacy for eligible patients.作者：L Vanek·2024·被引用次数：24—Semaglutidetreatment resulted in significant reduction in weight and BMI in patients with obesity undergoingdialysis, while maintaining an acceptable side ... In fact, one study indicated that semaglutide could help dialysis patients qualify for kidney transplants, with patients losing an average of 20.5 pounds after one year of treatment.

Safety and Tolerability in Dialysis Patients

A primary concern when considering new medications for patients on dialysis is safety. Fortunately, available data suggests that semaglutide is generally well-tolerated in this population.作者：A MIMA·2024·被引用次数：16—Our results showed thatoral semaglutide improved eGFR, although no significant differences were observed. Furthermore, no adverse events, including worsening ... Pooled analyses have indicated that semaglutide treatment was not associated with a higher proportion of SAEs (serious adverse events), including MACE (major adverse cardiovascular events) and all-cause mortality, among those initiating dialysis. Another study concluded that semaglutide appears safe for patients initiating dialysis.

Furthermore, the pharmacokinetics and tolerability of semaglutide do not appear to be significantly affected by hemodialysis, even in individuals with an estimated glomerular filtration rate (eGFR) below 15 mL/min, as observed in the PIONEER 5 trialSemaglutide in patients with kidney failure and obesity .... While gastrointestinal side effects, such as nausea and vomiting, are common with semaglutide use across all patient groups, they are generally manageable and similar to those seen in individuals without kidney impairment.作者：R Dobson·2024—The beneficial effect ofsemaglutideon his phosphate levels started within 1 month of initiation and was sustained until he received a kidney transplant in January 2022.Semaglutidealso improved the patient's glucose management, with fasting blood glucose in the range of. 6.2 to 6.5 mmol/L and HbA1c ... One study noted that semaglutide appears to be tolerated by most individuals with CKD 4 or greater despite associated gastrointestinal side effects similar to those observed in the general populationBurden of obesity in patients undergoing dialysis, and hopes .... For patients receiving peritoneal dialysis, semaglutide treatment in overweight or obese non-diabetic PD patients resulted in clinically meaningful weight loss, improved BP control, and enhanced dialysis adequacy作者：M Touzot·2022·被引用次数：27—We here reporttwo cases of obese hemodialysis (HD) patientswho were successfully treated with off-labeled semaglutide, a glucagon-like peptide receptor ....

Efficacy in Weight Management and Glycemic Control

The weight loss efficacy of semaglutide is a significant benefit for individuals on dialysis, where obesity can complicate management and recovery. Studies have reported substantial weight loss in this demographicSemaglutide in overweight non-diabetic peritoneal dialysis .... For example, one study found that semaglutide promotes weight loss in hemodialyzed adults with obesity, although treatment discontinuation due to adverse events was noted as a possibility. In some cases, semaglutide has also shown an impact on phosphate levels, with one patient experiencing a beneficial effect that was sustained until a kidney transplant.2025年11月4日—Treatment with the GLP-1 receptor agonistsemaglutide appears safe for patients initiating dialysis, as demonstrated in a pooled analysis ...

Beyond weight, semaglutide also contributes to improved glycemic control in patients with diabetes who are on dialysis作者：MW Taal·2025·被引用次数：13—Nevertheless, treatment withsemaglutideshould already be considered in persons with type 2 diabetes and CKD who are intolerant of SGLT2i and/ .... Research indicates that semaglutide improves glycemic control in patients with advanced CKD and T2DM (type 2 diabetes mellitus). Furthermore, oral semaglutide improved eGFR in some studies, although the impact on estimated glomerular filtration rate was not always statistically significant.

Addressing Specific Dialysis Modalities

The efficacy and safety of semaglutide are being investigated across different dialysis modalities:

* Hemodialysis (HD): Several studies have focused on obese hemodialysis patients, reporting successful treatment with semaglutide for weight loss. For instance, two cases of obese hemodialysis (HD) patients were reported to be successfully treated with off-label semaglutide. Another study highlighted the efficacy and safety of subcutaneous semaglutide in a patient with diabetes and obesity on incremental hemodialysis.6天前—In January of 2025,semaglutidebecame the first GLP-1 receptor agonist approved for worsening kidney disease, kidney failure, and death due to ...

* Peritoneal Dialysis (PD): As mentioned, semaglutide has shown promise in overweight or obese non-diabetic PD patients, leading to weight loss and better blood pressure control.

Conclusion

The growing body of evidence suggests a favorable profile for semaglutide in patients undergoing dialysis.For patients undergoing kidney dialysis, the use of GLP-1 receptor agonistsemaglutide showed safety, with no significant increase in ... Its ability to promote significant weight loss, improve glycemic control, and potentially offer renal protection makes it a valuable therapeutic optionThe Use of Semaglutide in Patients With Renal Failure-A .... While further research is ongoing, current findings indicate that semaglutide showed safety for patients on dialysis, with no significant increase in adverse eventsFor patients undergoing kidney dialysis, the use of GLP-1 receptor agonistsemaglutide showed safety, with no significant increase in .... The potential for semaglutide to aid in weight loss, improve eligibility for kidney transplants, and manage co-existing conditions like diabetes underscores its growing importance in the care of individuals with advanced kidney diseaseWeight loss drug proves effective in hemodialysis patients with .... As research continues, the nuanced application of semaglutide in dialysis patients is expected to further refine treatment strategies, offering hope for improved patient outcomes.